Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Apr-Jun;41(2):224-230.
doi: 10.1590/2175-8239-JBN-2018-0142. Epub 2019 Feb 4.

Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice: A retrospective study

[Article in English, Portuguese]
Aníbal Ferreira  1   2 , Bruno Pinto  3 , David Navarro  2 , João Aniceto  4 , Pedro L Neves  5 , Pedro Ponce  6   7
Affiliations
Multicenter Study

Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice: A retrospective study

[Article in English, Portuguese]
Aníbal Ferreira et al. J Bras Nefrol. 2019 Apr-Jun.

Abstract

Introduction: Hyperphosphatemia is a serious consequence of chronic kidney disease and has been associated with an increased risk for cardiovascular disease. Controlling serum phosphorus levels in patients on dialysis is a challenge for the clinicians and implies, in most cases, the use of phosphate binders (PB). Part of the reason for this challenge is poor adherence to treatment because of the high pill burden in this patient group.

Objective: To assess the real-world effectiveness of sucroferric oxyhydroxide (SO) in controlling serum phosphorus levels and determine the associated pill burden.

Methods: A multicenter, quantitative, retrospective, before-after study was conducted with patients receiving online hemodiafiltration. Patients who switched to SO as a part of routine care were included in the study. PB treatment, number of pills, serum phosphorus levels, and intravenous iron medication and dosage were collected monthly during the six months of treatment with either PB or SO.

Results: A total of 42 patients were included in the study. After switching from a PB to SO, the prescribed pills/day was reduced 67% from 6 pills/day to 2 pills/day (p < 0.001) and the frequency of pill intake was lowered from 3 times/day to 2 times/day (p < 0.001). During the treatment with SO, the proportion of patients with serum phosphorus ≤ 5.5 mg/dL increased from 33.3% at baseline to 45% after six months of treatment.

Conclusion: During the six-month follow-up with SO, serum phosphorus levels were controlled with one third of the pills/day compared to other PB.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Percentage of patients that presented with phosphorus levels ≤ 5.5 mg/dL at each timepoint of the study, grouped by treatment. MPT: months post-treatment; P: phosphorus.
Figure 2
Figure 2. Percentage of patients with a decrease in phosphorus ≥ 1 mg/dL at each timepoint of the study as compared to baseline, grouped by treatment. MPT: months post-treatment; P: phosphorus.
Figure 3
Figure 3. Side-by-side boxplots of phosphorus evolution over time from the start of the 6-month follow-up period of treatment with phosphate binders (-1M to -6M) until the end of the 6-month treatment period with sucroferric oxyhydroxide (1M to 6M).
See this image and copyright information in PMC

References

    1. Floege J. Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol 2016;29:329-40. - PubMed
    2. Floege J. Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol. 2016;29:329–340. - PubMed
    1. Tomey MI, Winston JA. Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health. Ann Glob Health 2014;80:69-76. - PubMed
    2. Tomey MI, Winston JA. Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health. Ann Glob Health. 2014;80:69–76. - PubMed
    1. Group KDIGOKC-MW. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2017;7:1-59. - PMC - PubMed
    2. Group KDIGOKC-MW KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl. 2017;7:1–59. - PMC - PubMed
    1. Cannata-Andía JB, Fernández-Martín JL, Locatelli F, London G, Gorriz JL, Floege J, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013;84:998-1008. - PubMed
    2. Cannata-Andía JB, Fernández-Martín JL, Locatelli F, London G, Gorriz JL, Floege J, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 2013;84:998–1008. - PubMed
    1. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382:1268-77. - PubMed
    2. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268–1277. - PubMed

Publication types